RxDoctor Payments Data

Upinder Singh

Infectious Disease · Iowa City, IANPI 1457487613

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,362 of the $8,362 with a category attached, or 100.0%. Gilead accounts for 73.1% of it on its own, with 1 other manufacturer making up the rest. Among infectious disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,362in general payments, 2019–2025

Across 9 payments — averaging $929.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • Regeneron$2K
$6,511,955in research payments, 2019–2025

Across 97 payments — averaging $67,134 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4.2M
  • Regeneron$2.3M

What the payments were for

  • Consulting fees$8,362100%

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead5$6,112
Regeneron4$2,250

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,362 in reported general payments places this provider in the 90th percentile of 58 infectious disease providers in Iowa.

See all infectious disease providers in Iowa

Other infectious disease in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →